SAN DIEGO

圣地亚哥

,

，

July 8, 2025

2025年7月8日

/PRNewswire/ --

/PRNewswire/ --

Circular Genomics, Inc.

环形基因组学公司

, a global leader in circular RNA (circRNA) biomarkers for precision neurology and psychiatry, today announced it has received a

，一家在精准神经学和精神病学环状RNA（circRNA）生物标志物领域的全球领导者，今天宣布已收到

$250,000

250,000美元

investment from the

投资来自

Alzheimer's Drug Discovery Foundation

阿尔茨海默病药物发现基金会

(ADDF) through its

通过其

Diagnostics Accelerator

诊断加速器

(DxA) program. The funding will support further studies of Circular Genomics' circRNA blood-based biomarkers for diagnosing and predicting the progression of Alzheimer's disease (AD).

(DxA) 计划。这笔资金将支持 Circular Genomics 进一步研究其基于环状 RNA 的血液生物标志物，用于诊断和预测阿尔茨海默病 (AD) 的进展。

Circular Genomics is developing the first blood-based tests that harness the potential of circRNA to enable personalized diagnosis and treatment for complex neurological and psychiatric conditions, such as AD. The investment, titled

Circular Genomics正在开发首个基于血液的测试，利用circRNA的潜力，为复杂的神经和精神疾病（如AD）提供个性化诊断和治疗。这项投资被称为

Alzheimer's Disease Specificity and Sensitivity Analyses of circRNA Blood Markers

阿尔茨海默病特异性和敏感性分析的circRNA血液标志物

, will support research conducted in partnership with

，将支持与合作伙伴共同开展的研究

Carlos Cruchaga

卡洛斯·克鲁查加

, PhD, Director, NeuroGenomics and Informatics Center at

，博士，神经基因组学与信息学中心主任，

Washington University

华盛顿大学

of Medicine in

医学在

St. Louis

圣路易斯

. The project will further study the potential of circRNA biomarkers to improve the diagnosis of AD and specifically distinguish it from other dementias, helping shift diagnostic uncertainty into clarity for patients and their healthcare providers.

该项目将进一步研究circRNA生物标志物在改善AD诊断方面的潜力，特别是将其与其他痴呆症区分开来，帮助将诊断的不确定性转变为患者及其医疗保健提供者的清晰诊断。

'We are honored to receive this investment from the ADDF as we continue to advance our suite of circRNA-based tools aimed at addressing the need for reliable diagnosis and prognosis for neurological conditions such as Alzheimer's and present several advantages over current protein-based biomarkers. Proper diagnosis and treatment of Alzheimer's can be challenging due to the complex nature of the disease, leading to misdiagnosis or delayed diagnosis, prolonging suffering for patients and their families,' said .

“我们很荣幸收到来自ADDF的投资，因为我们正在推进我们基于circRNA的工具套件，旨在满足对阿尔茨海默病等神经系统疾病可靠诊断和预后的需求，并且相比当前基于蛋白质的生物标志物具有多种优势。由于阿尔茨海默病的复杂性，其正确的诊断和治疗可能颇具挑战性，这会导致误诊或诊断延误，从而延长患者及其家人的痛苦，”该公司表示。

Nikolaos Mellios

尼古拉奥斯·梅利奥斯

, MD, PhD, Co-founder and Chief Scientific Officer of Circular Genomics. 'Our goal is to transform the diagnostic and treatment journey for patients —enabling earlier detection, better patient stratification, and more personalized clinical management of the disease.'

医学博士，Circular Genomics的联合创始人兼首席科学官。 “我们的目标是转变患者的诊断和治疗过程——实现更早的检测、更好的患者分层以及更个性化的疾病临床管理。”

Dr. Cruchaga, a renowned expert in neurogenomics and biomarker discovery, added, 'CircRNA biomarkers offer an exciting and promising approach for improving diagnostic accuracy and advancing personalized care for Alzheimer's as they may present several advantages over current protein-based biomarkers.

Cruchaga博士是神经基因组学和生物标志物发现领域的著名专家，他补充道：“环状RNA生物标志物提供了一种令人兴奋且前景广阔的方法，可以提高阿尔茨海默病的诊断准确性并推动个性化医疗的发展，因为它们可能比当前基于蛋白质的生物标志物具有多种优势。”

I'm looking forward to working with Circular Genomics to progress this innovative technology with the goal of improving outcomes for individuals at risk of AD through an earlier and more accurate diagnosis.'.

我期待与Circular Genomics合作，推动这项创新技术的发展，目标是通过更早和更准确的诊断来改善阿尔茨海默病风险个体的预后。

CircRNAs have been shown to play important roles in brain development, maturation, function, and aging and have been linked to many neurological and psychiatric disorders. Their abnormal expression in pathological states positions them as novel diagnostic and predictive biomarkers for numerous brain disorders.

circRNA 已被证明在大脑发育、成熟、功能和衰老中发挥重要作用，并且与许多神经和精神疾病有关。它们在病理状态下的异常表达使其成为多种脑部疾病的新诊断和预测生物标志物。

CircRNAs are mainly expressed in brains but can also be measured in blood, representing a window into overall brain health. The research will further quantify and characterize blood brain-derived circRNA biomarkers to help create best-in-class tools for predicting AD's progression and enabling a more accurate diagnosis..

circRNA主要在大脑中表达，但也可以在血液中检测到，是反映整体大脑健康的一个窗口。该研究将进一步量化和表征血液脑源性circRNA生物标志物，以帮助创建预测AD进展和实现更准确诊断的最佳工具。

'Circular Genomics' work represents the type of innovative science needed to transform how we detect and diagnose Alzheimer's disease,' said

“循环基因组学”的工作代表了我们所需要的创新科学，以改变我们检测和诊断阿尔茨海默病的方式，

Howard Fillit

霍华德·菲利特

, MD, Co-Founder and Chief Science Officer at the ADDF. 'By investing in accessible and scalable biomarker technologies, such as this one, we aim to accelerate earlier and more accurate diagnosis, which is a critical step towards moving to treating Alzheimer's with precision medicine, so the right patients get the right treatments at the right time.'.

，医学博士，ADDF的联合创始人兼首席科学官。“通过投资于可及且可扩展的生物标志物技术，例如这一技术，我们的目标是加速更早和更准确的诊断，这是迈向使用精准医学治疗阿尔茨海默病的关键一步，以便让合适的患者在合适的时间获得合适的治疗。”

The DxA is a

DxA 是一个

$100M

1亿美元

global research initiative aimed at fast-tracking the development of biomarkers and diagnostic tools to aid in the detection and diagnosis of Alzheimer's and related dementias.

全球研究计划，旨在加速开发生物标志物和诊断工具，以帮助检测和诊断阿尔茨海默病及相关痴呆症。

About Circular Genomics

关于循环基因组学

Circular Genomics is the world-leading developer of circular RNA-based precision medicine tools, data and diagnostics for precision neurology and psychiatry. Leveraging exclusive licenses and pioneering technologies in circular RNA, Circular Genomics is aiming to reshape the standard of care for major depressive disorder and other neurological and psychiatric diseases such as like Alzheimer's disease, Parkinson's disease, and Bipolar disorder.

Circular Genomics 是全球领先的基于环状RNA的精准医学工具、数据和诊断开发商，专注于精准神经学和精神病学。通过利用环状RNA领域的独家许可和开创性技术，Circular Genomics 旨在重塑重度抑郁症及其他神经系统和精神疾病（如阿尔茨海默病、帕金森病和双相情感障碍）的治疗标准。

Initial products include assays to assess and tailor optimal treatment protocols for individual patients, resulting in more personalized and effective care. For additional details, please visit.

初始产品包括用于评估和定制个别患者最佳治疗方案的检测，从而提供更加个性化和有效的护理。欲了解更多信息，请访问。

www.circulargenomics.com

www.circulargenomics.com

.

。

About the Alzheimer's Drug Discovery Foundation (ADDF)

关于阿尔茨海默病药物发现基金会 (ADDF)

Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry.

成立于1998年，由伦纳德·A. 和罗纳德·S. 劳德创立的阿尔茨海默病药物发现基金会致力于快速加速预防、治疗和治愈阿尔茨海默病的药物研发。ADDF是唯一一家专注于为阿尔茨海默病药物开发提供资金的公共慈善机构，采用风险慈善模式支持学术界和生物技术行业的研究。

The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid.

ADDF的领导和贡献在推动首个阿尔茨海默病PET扫描（Amyvid）方面发挥了关键作用。

®

®

) and blood test (PrecivityAD

）和血液测试（PrecivityAD

®

®

) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit:

）推向市场，并且为当前强大而多样化的药物研发管道提供动力。通过其捐赠者的慷慨解囊，ADDF已授予超过3.7亿美元，用于资助在21个国家开展的765个阿尔茨海默病药物发现项目、生物标志物项目和临床试验。欲了解更多信息，请访问：

http://www.alzdiscovery.org/

http://www.alzdiscovery.org/

.

。

About The Diagnostic Accelerator (DxA)

关于诊断加速器 (DxA)

The

The

Diagnostics Accelerator

诊断加速器

, created in July 2018, is a $100 million global research initiative from partners including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal Degeneration, among others, to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias..

，于2018年7月创立，是一项由ADDF联合创始人伦纳德·A·劳德、比尔·盖茨、杰夫·贝索斯、麦肯齐·斯科特、杜比家族、查尔斯和海伦·舒瓦布基金会、前颞叶退化协会等合作伙伴发起的1亿美元全球研究计划，旨在开发用于阿尔茨海默病及相关痴呆早期检测的新型生物标志物。

This research initiative is dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias and advance the clinical development of more targeted treatments. Through translational research awards and access to consulting support from industry experts, this program will challenge, assist and fund the research community in both academia and industry to develop novel peripheral and digital biomarkers..

这项研究计划致力于加速开发可负担且可获取的生物标志物，用于诊断阿尔茨海默病及相关痴呆症，并推动更有针对性的治疗方法的临床开发。通过转化研究奖项以及行业专家的咨询服务支持，该计划将挑战、协助并资助学术界和产业界的研究社区，以开发新型的外周和数字生物标志物。

About the Neurogenomics and Informatics Center (NGI) at

关于神经基因组学与信息学中心 (NGI)

Washington University

华盛顿大学

The NGI was founded in 2020 with the goal of identifying new biomarkers, and causal and druggable targets for neurological diseases, by performing deep molecular profiling of human samples. NGI investigators use a data-driven approach and integrate multi-tissue and multi-omic data with AI/ML to understand the biological processes implicated on Alzheimer's disease, Parkinson's disease, stroke and other neurodegenerative diseases which will lead to personalize biomarkers and treatments..

NGI 成立于 2020 年，目标是通过对人体样本进行深入的分子分析，识别出新的生物标志物以及神经疾病的相关靶点和可成药靶点。NGI 的研究人员采用数据驱动的方法，整合多组织和多组学数据，并结合人工智能/机器学习来理解与阿尔茨海默病、帕金森病、中风及其他神经退行性疾病相关的生物学过程，从而实现个性化生物标志物和治疗方法的开发。

SOURCE Circular Genomics

来源：Circular Genomics

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用